Get App
Download App Scanner
Scan to Download
Advertisement
This Article is From Oct 20, 2017

Dr. Reddy’s Recalls Famotidine Tablets From U.S. Market

Dr. Reddy’s Recalls Famotidine Tablets From U.S. Market
Workers quality check containers at a Dr Reddy’s manufacturing plant (Photographer: Amit Bhargava/Bloomberg)

Dr. Reddy's Laboratories Ltd. has initiated voluntarily recall of over half a million Famotidine tablets bottles from the U.S. market as the drug failed impurities or degradation specifications.

According to a notification put up by the U.S. Food and Drug Administration, the recall is being made under Class-III classification, which is described as “a situation in which use of or exposure to a violative product is not likely to cause adverse health consequences”.

“Failed impurities/degradation specifications: Famotodine has an out of specification result for an individual related substance observed during routine stability testing of a batch for related substances -impurity 8 at 24 month stability interval,” the notification said on the reasons for recall.

As many as 5,69,376 bottles of Famotidine tablets, 10 mg belonging to multiple lots packaged in 30-count, are being recalled nationwide.

The drug is an over-the-counter (OTC) product used to treat and prevent ulcers in stomach and intestines.

Essential Business Intelligence, Continuous LIVE TV, Sharp Market Insights, Practical Personal Finance Advice and Latest Stories — On NDTV Profit.

Newsletters

Update Email
to get newsletters straight to your inbox
⚠️ Add your Email ID to receive Newsletters
Note: You will be signed up automatically after adding email

News for You

Set as Trusted Source
on Google Search